NOVOMEDLINK™

This page contains information about Novo Nordisk products.

NovoLog® significantly
reduces postprandial glucose
(PPG) levels1-3

A pump study in type 1 diabetes compared blood glucose profiles with
NovoLog® and the rapid-acting insulin analogs insulin lispro and insulin
glulisine over approximately 10 months. According to this study’s
crossover design, each subject used each insulin over a 13-week period,
in 1 of 3 sequences. The graph below shows mean 7-point blood glucose
profiles at the end of the study.

Mean PPG levels for NovoLog®, insulin glulisine, and
insulin lispro

7-point self-monitored plasma glucose in the last week1

7-point self-monitored plasma glucose in the last week

AB=after breakfast; AD=after dinner; AL=after lunch; BD=before dinner;
BL=before lunch; FG=fasting glucose; N=night at 3 am

A 39-week, randomized, controlled, multinational, open-label, 3-way crossover
study enrolling 256 adult patients with type 1 diabetes assigned to 1 of 3 treatment
groups (glulisine–NovoLog®–lispro; NovoLog®–lispro–glulisine; lispro–glulisine–
NovoLog®) and then “crossed over” (13 weeks per each intervention).

Adapted from van Bon et al, 2011.1

Rate of hypoglycemia versus insulin glulisine:1

  • Significantly lower mean rate of symptomatic hypoglycemia*
    per patient-year (NovoLog® 65.0, insulin glulisine 73.8) (P=0.008)
  • Rate of major hypoglycemia was not different among the 3 insulin groups

*<70 mg/dL with symptoms.

NovoLog® provides significantly better mean PPG
levels after 3 meals versus regular human insulin2,3

In a 6-month study of patients with type 1 diabetes who added mealtime
injections of either NovoLog® or regular human insulin to a basal regimen
with NPH human insulin, NovoLog® provided significantly lower PPG levels
than regular human insulin— a difference of 30 mg/dL.

significantly reduces

A 6-month, randomized, open-label, parallel-group
study enrolling 882 patients who had had type 1
diabetes for at least 18 months. Patients taking NPH
insulin were randomized to either NovoLog® or regular
human insulin as part of basal–bolus therapy. There
was a 6-month optional extension of this trial.2

Having better conversations with
your patients

Explaining the disease progression of diabetes in patient-friendly terms

Watch video

Mean PPG levels after dinner versus insulin lispro in
patients with type 1 diabetes4

The graph below shows plasma glucose profiles in patients with type 1
diabetes who were assigned to NovoLog® or insulin lispro in pump use.
(Another branch of the study used buffered human insulin, which is no
longer available in the United States. Those results are not shown here.)
After 16 weeks, NovoLog® provided better mean glucose levels after
dinner than insulin lispro.

Pre- and postmeal blood glucose values at 16 weeks4

Pre- and postmeal blood glucose values at 16 weeks

A 16-week, open-label, randomized, parallel-group study enrolling 146 patients
with type 1 diabetes for at least 12 months. Patients were randomized to receive
NovoLog®, insulin lispro, or buffered regular insulin as part of continuous
subcutaneous insulin infusion (CSII) therapy.

Buffered regular insulin is no longer manufactured in the United States.

Adapted from Bode et al, 2002.4

In the same study, no patients in the NovoLog®
or lispro group reported a major hypoglycemic event
(defined as requiring IV glucose).4

Shown are patient-reported hypoglycemic events (symptoms with blood
glucose <50 mg/dL) per patient per month for NovoLog® and insulin lispro,
in 2 periods: a 4-week run-in period and a 12-week maintenance period.

Rate of hypoglycemic episodes3

Rate of hypoglycemic episodes

A 16-week, open-label, randomized, parallel-group study enrolling 146 patients with
type 1 diabetes for at least 12 months. Patients were randomized to receive NovoLog®,
insulin lispro, or buffered regular insulin
as part of continuous subcutaneous insulin infusion (CSII) therapy.

Buffered regular insulin is no longer manufactured in the United States.
Adapted from Bode et al, 2002.4

Related Support

View eSeminar Watch a clinical overview of the efficacy, safety, and tolerability
of NovoLog® for patients with type 1 diabetes.

Check formulary status Search the current formulary status of NovoLog® in your area
to help find coverage for your patients.

Up Next

See how NovoLog® helps patients lower A1C levels5,6

References:

  1. van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes:
    a randomized controlled trial. Diabetes Technol Ther. 2011;13(6):1-8.
  2. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23(5):583-588.
  3. Data on file, Novo Nordisk, Inc., Princeton, NJ.
  4. Bode B, Weinstein R, Bell D, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25(3):439-444.
  5. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract. 2011;17(5):727-736.
  6. Holman RR, Farmer AJ, Davies MJ, et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736-1747.

  1. NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

    NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

    NovoLog® Important Safety Information

    NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

    NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent. Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

    Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

    Needles and NovoLog® FlexPen® must not be shared.

    NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes under the age of two.

    Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

    Please click hereclick here for Prescribing Information.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S.
NovoMedLink™ is a trademark of Novo Nordisk A/S.
This is presented in Macromedia Flash. If you don't have the proper plug-in, you can download it free by clicking here